MedPath

Prostate Cancer Molecular Medicine (PCMM).

Recruiting
Conditions
Prostate cancer / prostaatkanker
Registration Number
NL-OMON27495
Lead Sponsor
Erasmus MC, NKI-AvL, UMCG, UMC
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
400
Inclusion Criteria

Group 1:

1. Planned to undergo prostate biopsies according to standard practice;

Exclusion Criteria

Group 1 and group 2:

1. Known allergy to contrast agents or sulphur hexafluoride micro bubbles;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Construction of a Dutch multicenter prospective biorepository for validation of biomarker and imaging products.
Secondary Outcome Measures
NameTimeMethod
1. Newly developed biomarkers and imaging tools that can improve the diagnosis, prognosis and therapy monitoring for prostate cancer;<br /><br>2. An IT infrastructure for the integration of the complex information from biomarker analysis and (molecular) imaging, next to individual clinical data and biobank data, allowing for the future development of a Clinical Decision Support System (CDSS) that optimizes clinical decision making.
© Copyright 2025. All Rights Reserved by MedPath